Osteoporosis Biosimilar OK'd; New Endo Guidelines; A Hot Spot for Stealing Ozempic

Watchdoq February 18, 2025
(MedPage Today) -- The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture and increasing bone mass in several patient populations, said maker Samsung Bioepis.
A group of 50...

Read Full Article